Citations

Showing 10 of 108083 citations.

Challenges and solutions to sustaining paediatric weight management programs in the United States
Christison, Amy L. , Kumar, Seema , Novick, Marsha B. , Stratbucker, William, Sweeney, Brooke , Vidmar, Alaina P. , Kirk, Shelley, Vidmar, Alaina , Christison, Amy , Ariza, Adolfo J. , Fernandez, Cristina, Santos, Melissa

Mayo Clinic

Clinical Obesity | January 12, 2023 | Volume: 13 | Issue: 3 | Pages: No page available

10.1111/cob.12577 | PMID 36631245 Get It

SummaryPaediatric weight management (PWM) programs in the United States (US) face challenges in providing sustainable multidisciplinary care for patients. The aim of this study was to report PWM program approaches to sustaining program delivery. A survey of 39 PWM programs was administered to identify challenges and solutions to program sustainability. Common and useful strategies for optimizing reimbursement for services included the use of applicable reimbursable diagnostic codes and management, billing for assessments and non‐medical personnel services, and the use of hospital outpatient department clinic billing. Increasing clinical breadth and capacity was achieved by offering telemedicine and other services, such as psychotherapy, pharmacotherapy, and metabolic and bariatric surgery, as well as active management of schedules. Securing institutional and extramural funding was also reported. One of the positive changes during the pandemic was the fast adoption of telemedicine services. Although delivering sustainable evidence‐based multidisciplinary PWM under the current US payment models has its challenges, PWM programs implement practical operational strategies to support this work.
Timing and causative organisms associated with modern inflatable penile prosthesis infection: an institutional retrospective
Habashy, Engy, Yang, David Y. , MBBCh, Mohamed Ahmed, Trost, Landon , Ziegelmann, Matthew , Köhler, Tobias , Bole Md, Raevti, Habashy Md, Engy, Yang Md, David , Ahmed MBBCh, Mohamed, Ziegelmann Md, Matthew, Helo Md, Sevann, Kohler Md, Tobias, Bole, Raevti , Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | January 12, 2023 | Volume: 20 | Issue: 1 | Pages: 107-112

10.1093/jsxmed/qdac001 | PMID 36897233 Get It

AbstractBackgroundThe advent of antibiotic-coated devices has reduced the rate of inflatable penile prosthesis (IPP) infections; however, this may have altered microbial profiles when infections do occur.AimTo describe the timing and causative organisms behind infection of infection retardant–coated IPPs in the context of our institution’s perioperative antimicrobial protocols.MethodsWe retrospectively reviewed all patients undergoing IPP placement at our institution from January 2014 to January 2022. In all patients, perioperative antibiotic administration was congruent with American Urological Association guidelines. Boston Scientific devices are impregnated with InhibiZone (rifampin and minocycline), and all Coloplast devices were soaked in rifampin and gentamicin. Intraoperative irrigation was performed with betadine 5% irrigation prior to November 2016 and with vancomycin-gentamicin solution afterward. Cases involving prosthesis infection were identified, and variables were extracted from the medical record. Descriptive and comparative statistics were tabulated to identify clinical characteristics, including patient comorbidities, prophylaxis regimen, symptom onset, and intraoperative culture result. We previously reported an increased infection risk with Betadine irrigation and stratified results accordingly.OutcomesThe primary outcome was time to infectious symptoms, while the secondary outcome was description of device cultures at the time of explantation.ResultsA total of 1071 patients underwent IPP placement over 8 years with an overall infection rate of 2.6% (28/1071). After discontinuation of Betadine, the overall infection rate was significantly lower at 0.9% (8/919) with a relative risk of 16.9 with Betadine (P < .0001). Primary procedures represented 46.4% (13/28). Of 28 patients with infection, only 1 had no identified risk factors; the remainder included Betadine at 71% (20/28), revision/salvage procedure at 53.6% (15/28), and diabetes at 50% (14/28). Median time to symptoms was 36 days (IQR, 26-52); almost 30% of patients had systemic symptoms. Organisms with high virulence, or ability to cause disease, were found in 90.5% (19/21) of positive cultures.Clinical ImplicationsOur study revealed a median time to symptoms of just over 1 month. Risk factors for infection were Betadine 5% irrigation, diabetes, and revision/salvage cases. Over 90% causative organisms were virulent, demonstrating a microbial profile trend since antibiotic coating development.Strengths and LimitationsThe large prospectively maintained database is a strength along with the ability to follow specific changes in perioperative protocols. The retrospective nature of the study is a limitation as well as the low infection rate, which limits certain subanalyses from being performed.ConclusionIPP infections present in a delayed manner despite the rising virulence of infecting organisms. These findings highlight areas for improvement in perioperative protocols in the contemporary prosthetics era.
Use of Obstetric and Gynecologic Hospitalists Is Associated With Decreased Severe Maternal Morbidity in the United States
Torbenson, Vanessa E. , Tatsis, Vasiliki, Butler, Jennifer , Kjerulff, Lucy, McLaughlin, G. Blake, Stika, Catherine S. , Tappin, Dyanne, VanBlaricom, Amy, Mehta, Ramila A. , McCue, Brigid , Mehta, Ramila, Bradley, Sarah L., McLaughlin, G. Blake, Branda, Megan E.

Mayo Clinic

Journal of Patient Safety | January 11, 2023 | Volume: 19 | Issue: 3 | Pages: 202-210

10.1097/pts.0000000000001102 | PMID 36630491 Get It

Objectives This study aimed to evaluate the prevalence of obstetric and gynecologic (Ob/Gyn) hospitalists and determine if an association exists between the presence of Ob/Gyn hospitalists and severe maternal morbidity (SMM). Methods This observational study included data from hospitals listed in the USA TODAY’s 2019 article titled, “Deadly deliveries: Childbirth complication rates at maternity hospitals.” Telephone and email surveys of staff in these hospitals identified the presence or absence of continuous providers in the hospital 24 hours, 7 days a week (24/7 coverage) and the types of providers who are employed, then compared these responses with the SMM cited by USA TODAY. Results Eight hundred ten hospitals were contacted, with participation from 614 labor and delivery units for a response rate of 75.8%. Fifty-seven percent of units were staffed with 24/7 coverage, with 46% of hospitals’ coverage primarily provided by an Ob/Gyn hospitalist and 54% primarily by a nonhospitalist OB/Gyn provider. The SMM and presence of 24/7 coverage increased with the level of neonatal care and delivery volume. Of hospitals with 24/7 coverage, those that primarily used Ob/Gyn hospitalists had a lower SMM for all mothers (1.7 versus 2.0, P = 0.014) and for low-income mothers (1.9 versus 2.30, P = 0.007) than those who primarily used nonhospitalist OB/Gyn providers. Conclusions Severe maternal morbidity increases with delivery volume, level of neonatal care, and 24/7 coverage. Of hospitals with 24/7 coverage, units that staff with Ob/Gyn hospitalists have lower levels of SMM than those that use nonhospitalist Ob/Gyn providers.
Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021
Herges, Joseph R. , Galindo, Rodolfo J. , Neumiller, Joshua J. , Heien, Herbert C., Umpierrez, Guillermo E. , McCoy, Rozalina G. , Umpierrez, Guillermo E. , McCoy, Rozalina Grubina , Galindo, Rodolfo J , Neumiller, Joshua J.

Mayo Clinic

Diabetes Care | January 11, 2023 | Volume: 46 | Issue: 3 | Pages: 620-627

10.2337/dc22-1564 | PMID 36630526 Get It

OBJECTIVETo characterize contemporary trends in glucagon fill rates and expenditures in a nationwide cohort of adults with diabetes overall and by key demographic and clinical characteristics.RESEARCH DESIGN AND METHODSIn this retrospective cohort study, we examined 1) glucagon fill rates per 1,000 person-years and 2) patient out-of-pocket and health plan costs per filled glucagon dose among adults with diabetes included in OptumLabs Data Warehouse between 1 January 2011 and 31 March 2021.RESULTSThe study population comprised 2,814,464 adults with diabetes with a mean age of 62.8 (SD 13.2) years. The overall glucagon fill rate decreased from 2.91 to 2.28 per 1,000 person-years (−22%) over the study period. In groups at high risk for severe hypoglycemia, glucagon fill rates increased from 22.46 to 36.76 per 1,000 person-years (64%) among patients with type 1 diabetes, 11.64 to 16.63 per 1,000 person-years (43%) among those treated with short-acting insulin, and 16.08 to 20.12 per 1,000 person-years (25%) among those with a history of severe hypoglycemia. White patients, women, individuals with high income, and commercially insured patients had higher glucagon fill rates compared with minority patients, males, individuals with low income, and Medicare Advantage patients, respectively. Total cost per dosing unit increased from $157.97 to $275.32 (74%) among commercial insurance beneficiaries and from $150.37 to $293.57 (95%) among Medicare Advantage beneficiaries.CONCLUSIONSGlucagon fill rates are concerningly low and declined between 2011 and 2021 but increased in appropriate subgroups with type 1 diabetes, using short-acting insulin, or with a history of severe hypoglycemia. Fill rates were disproportionately low among minority patients and individuals with low income.
The Apraxia of Speech Rating Scale: Reliability, Validity, and Utility
Duffy, Joseph R. , Martin, Peter R. , Clark, Heather M. , Utianski, Rene L. , Whitwell, Jennifer L. , Josephs, Keith A. , Strand, Edythe A. , Whitwell, Jennifer L , Josephs, Keith A , Utianski, Rene L , Clark, Heather M , Duffy, Joseph R , Whitwell, Jennifer L.

Mayo Clinic

American Journal of Speech-Language Pathology | January 11, 2023 | Volume: 32 | Issue: 2 | Pages: 469-491

10.1044/2022_ajslp-22-00148 | PMID 36630926 Get It

Purpose: The purpose of this study was to examine the interrater reliability and validity of the Apraxia of Speech Rating Scale (ASRS-3.5) as an index of the presence and severity of apraxia of speech (AOS) and the prominence of several of its important features. Method: Interrater reliability was assessed for 27 participants. Validity was examined in a cohort of 308 participants (120 with and 188 without progressive AOS) through item analysis; item-Total score correlations; correlations among ASRS Total score and component subscores and independent clinical ratings of AOS, dysarthria and aphasia severity, intelligibility, and articulatory errors, as well as years postonset and age; and regression models assessing item and Total score prediction of AOS presence. Results: Interrater reliability was good or excellent for most items and excellent for the Total score. Item and Total score analyses revealed good separation of participants with versus without AOS. Inter-item and item-Total score correlations were generally moderately high as were correlations between the ASRS Total score and independent ratings of AOS severity, intelligibility, and articulatory errors. The Total score was not meaningfully correlated with ratings of aphasia and dysarthria severity, years postonset, or age. Total scores below 7 and above 10 revealed excellent diagnostic sensitivity and specificity for AOS. The presence of eight or more abnormal features was also highly predictive of AOS presence. Conclusions: The ASRS-3.5 is a reliable and valid scale for identifying the presence and severity of AOS and its predominant features. It has excellent sensitivity to AOS presence and excellent specificity relative to aphasia and dysarthria in patients with neurodegenerative disease. Supplemental Material: https://doi.org/10.23641/asha.21817584
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
Thurber, Kristina M., Otto, Ashley O, Stricker, Shawna L, Otto, Ashley

Mayo Clinic

American Journal of Health-System Pharmacy | January 11, 2023 | Volume: 80 | Issue: 8 | Pages: 487-494

10.1093/ajhp/zxad009 | PMID 36629265 Get It

AbstractPurposeProton pump inhibitors (PPIs) are widely prescribed medications. Various adverse clinical effects of PPIs have been reported in the literature, particularly over the past decade. The purpose of this article is to review published data primarily describing adverse effects associated with PPI use and to help clinicians determine which patients may still benefit from therapy despite safety concerns.SummaryAssociations between PPIs and the following have been described: bone fracture, acute and chronic kidney disease, gastrointestinal infections, deficiencies in vitamin B12 and magnesium, and coronavirus disease 2019 and respiratory infections. For inclusion in this review, studies must have evaluated potential adverse events associated with PPIs as a primary or secondary objective. Increased risks of bone fracture, acute and chronic kidney disease, gastrointestinal infections, and magnesium deficiency were consistently reported, albeit mostly in studies involving low-quality data (case-control and/or observational studies) and subject to bias. In the only pertinent randomized controlled trial to date, chronic pantoprazole use was associated with a greater risk of enteric infections relative to placebo use; there was no significant between-group difference in any other adverse event evaluated. PPIs continue to be recommended by the American College of Gastroenterology as a first-line treatment for management of gastroesophageal reflux disease and in the acute period following upper gastrointestinal and ulcer bleeding.ConclusionHigher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.
Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment
Zanwar, Saurabh , Gertz, Morie A. , Muchtar, Eli

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 11, 2023 | Volume: 21 | Issue: 1 | Pages: 83-90

10.6004/jnccn.2022.7077 | PMID 36630897 Get It

Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder with multiple clinical presentations. The diagnosis of AL amyloidosis requires a high index of suspicion, making a delay in diagnosis common, which contributes to the high early mortality seen in this disease. Establishing the diagnosis of AL amyloidosis requires the demonstration of tissue deposition of amyloid fibrils. A bone marrow biopsy and fat pad aspirate performed concurrently have a high sensitivity for the diagnosis of AL amyloidosis and negate the need for organ biopsies in most patients. An accurate diagnosis requires amyloid typing via additional testing, including tissue mass spectrometry. Prognostication for AL amyloidosis is largely driven by the organs impacted. Cardiac involvement represents the single most important prognostic marker, and the existing staging systems are driven by cardiac biomarkers. Apart from organ involvement, plasma cell percentage on the bone marrow biopsy, specific fluorescence in situ hybridization findings, age at diagnosis, and performance status are important prognostic markers. This review elaborates on the diagnostic testing and prognostication for patients with newly diagnosed AL amyloidosis.
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
Cameron, David , Bruzzone, Marco , Massarotti, Claudia , El-Abed, Sarra , Wang, Yingbo , Lecocq, Christophe, Rolyance, Rebecca, Sohn, Joohyuk , Arecco, Luca , Pistilli, Barbara , Ruddy, Kathryn J. , Saura, Cristina , Piccart, Martine , Cameron, David , El-Abed, Sarra , Sohn, Joohyuk , Saura, Cristina , Bruzzone, Marco , Lambertini, Matteo , Ceppi, Marcello , Anderson, Richard A. , Franzoi, Maria Alice , Nucíforo, Paolo , Pusztai, Lajos , Latocca, Maria Maddalena , Ballestrero, Alberto , Mastro, Lucia Del , Peccatori, Fedro A , Partridge, Ann H. , Untch, Michael , Cosimo, Serena Di , Azambuja, Evandro de , Demeestere, Isabelle

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 11, 2023 | Volume: 21 | Issue: 1 | Pages: 33-41.e16

10.6004/jnccn.2022.7065 | PMID 36634607 Get It

Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment–induced gonadotoxicity. Patients and Methods: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the “biological window” of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy). Results: The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33–42 years). AMH values at the 3 time points differed significantly (P<.001). At baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56–2.62 ng/mL). At week 2, a small but significant reduction in AMH levels was observed (median, 1.10 ng/mL; IQR, 0.45–2.09 ng/mL; P<.001). At surgery, a larger significant decline in AMH levels was observed (median, 0.01 ng/mL; IQR, 0.01–0.03 ng/mL; P<.001). Although the type of anti-HER2 treatment (trastuzumab and/or lapatinib) did not seem to impact the results, age and pretreatment ovarian reserve had a major influence on treatment-induced gonadotoxicity risk. Conclusions: This NeoALTTO biomarker analysis showed that anti-HER2 therapies alone had limited gonadotoxicity but that the addition of weekly paclitaxel resulted in marked AMH decline with possible negative implications for subsequent ovarian function and fertility.
Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology
Sholl, Lynette M. , Naso, Julia , Sholl, Lynette , Lo, Ying‐Chun

Mayo Clinic

Journal of Surgical Oncology | January 11, 2023 | Volume: 127 | Issue: 2 | Pages: 244-257

10.1002/jso.27184 | PMID 36630101 Get It

AbstractThe pathologic assessment of lung cancers provides essential guidance to the surgeon and oncologist who are considering the best treatment strategies for patients with both early and advanced‐stage disease. The management of patients with lung cancer is predicated first and foremost on access to an accurate diagnosis, even when the sample size is limited, as is often the case with use of modern, minimally invasive sampling techniques. Once the diagnosis and disease stage are established, predictive biomarker testing may be essential, particularly for those patients with nonsmall cell lung carcinoma (NSCLC) being considered for immunotherapy or genomic biomarker‐driven targeted therapy. This review will discuss the best practices for the diagnosis of NSCLC using morphology and immunohistochemistry, thus providing the surgeon with needed information to understand and critically evaluate pathology reports. Controversial and evolving topics including tumor spread through airspaces, evaluation of multiple tumors, and staging based on invasive tumor size will be addressed. Clinical genomic profiling in NSCLC is driven by published guidelines and reflects evidence based on clinical trials and regulatory approvals. In this fast‐moving space, surgeons should be aware of the critical immunohistochemical and genomic biomarkers that drive systemic therapy decisions and anticipate when such testing will be required, both to ensure adequate sampling and to advise the pathologist when tumor material will be required for biomarker analysis. The basic approaches to and sample requirements for molecular biomarker testing will be addressed. As biomarker testing moves exclusively from advanced‐stage patients into earlier stage disease, the surgeon should be aware of the relevant markers and work with the pathologist and oncologist to ensure that this information is available to facilitate timely access to therapies not just in the advanced setting, but in consideration of neoadjuvant and adjuvant care.
Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment
Guerra, Carmen E. , Pressman, Alice , Hurley, Patricia A. , Garrett‐Mayer, Elizabeth , Bruinooge, Suanna S. , Howson, A. G. , Kaltenbaugh, Melinda , Williams, Jen Hanley, Boehmer, Leigh , Bernick, Lea Ann, Byatt, Leslie, Crews, Jennie R. , McCaskill‐Stevens, Worta , Merrill, Janette K. , Nowakowski, Greg, Patel, Manali I. , Zwicker, Victoria, Oyer, Randall A. , Pierce, Lori J. , Guerra, Carmen E , Hurley, Patricia , Howson, Alexandra , Hanley Williams, Jen , Charlot, Marjory , Merrill, Janette , Nowakowski, Grzegorz S , Patel, Manali I , Ramirez, Amelie G , Oyer, Randall A , Bruinooge, Suanna Steeby , Garrett-Mayer, Elizabeth , Charlot, Marjory , Fashoyin-Aje, Lola

Mayo Clinic

JCO Oncology Practice | January 11, 2023 | Volume: 19 | Issue: 4 | Pages: e581-e588

10.1200/op.22.00560 | PMID 36630663 Get It

Clinical trial participants do not reflect the racial and ethnic diversity of people with cancer. ASCO and the Association of Community Cancer Centers collaborated on a quality improvement study to enhance racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials. The groups conducted a pilot study to examine the feasibility, utility, and face validity of a two-part clinical trial site self-assessment to enable diverse types of research sites in the United States to (1) review internal data to assess racial and ethnic disparities in screening and enrollment and (2) review their policies, programs, procedures to identify opportunities and strategies to improve EDI. Overall, 81% of 62 participating sites were satisfied with the assessment; 82% identified opportunities for improvement; and 63% identified specific strategies and 74% thought the assessment had potential to help their site increase EDI. The assessment increased awareness about performance (82%) and helped identify specific strategies (63%) to increase EDI in trials. Although most sites (65%) were able to provide some data on the number of patients that consented, only two sites were able to provide all requested trial screening, offering, and enrollment data by race and ethnicity. Documenting and evaluating such data are critical steps toward improving EDI and are key to identifying and addressing disparities more broadly. ASCO and Association of Community Cancer Centers will partner with sites to better understand their processes and the feasibility of collecting screening, offering, and enrollment data in systematic and automated ways.